Fig. 10.

Roxadustat protects mice against Mn neurotoxicity. (A) qRT-PCR assays from indicated tissues of C57BL/6J mice harvested after treatment with vehicle or roxadustat (10 mg/kg body weight daily intraperitoneally) for 4 wk (starting at ∼4 wk of age). Mean expression in vehicle-treated mice was normalized to 1. n = 5/treatment. Mean ± SE, *P < 0.05 by Student’s t test. (B) Open-field activity data for vertical movement in mice treated with vehicle or roxadustat as described in A along with or without exposure to Mn in drinking water (∼30 mg absolute Mn/kg body weight daily). Treatment was at ages and for the duration described in A. Open-field analysis was performed before euthanasia. n = 5/group. Mean ± SE, *P < 0.05 by repeated measures two-way ANOVA and Tukey Kramer post hoc test for indicated comparisons. (C) Inductively coupled plasma mass spectrometry metal analyses from indicated tissues of animals used for neurobehavior analyses in B. n = 5/group. Mean ± SE. Indicated P values are for two-way ANOVA analyses using roxadustat and Mn as independent variables; n.s., not significant.